ISSN: 1470-269X

Journal Home

Journal Guideline

The Pharmacogenomics Journal Q2 Unclaimed

Nature Publishing Group United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Pharmacogenomics Journal is a journal indexed in SJR in Genetics and Pharmacology with an H index of 95. It has a price of 3190 €. It has an SJR impact factor of 0,659 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,659.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Pharmacology (Q2) Genetics (Q3) Molecular Medicine (Q3)

Price

3190 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,659

SJR Impact factor

95

H Index

28

Total Docs (Last Year)

194

Total Docs (3 years)

1215

Total Refs

524

Total Cites (3 years)

193

Citable Docs (3 years)

2.58

Cites/Doc (2 years)

43.39

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Journal of Human Genetics Q2
Gene: X Q2
Advances in Biological Regulation Q2
Genes Chromosomes and Cancer Q2
Human Gene Therapy Q2

Compare this journals

Aims and Scope

Best articles by citations

Improved biological and transcriptional activity of monopegylated interferon-a-2a isomers

Cytoprotection against thermal injury: evaluation of herbimycin A by cell viability and cDNA arrays

Implications of pharmacogenomics in oral health

In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor

NAT - from bugs to brains An overview of the 2nd International Workshop on the arylamine N-acetyltransferases

Age at onset: important marker of genetic heterogeneity in Alzheimer's disease

Genetic factors influencing Pyrimidine-antagonist chemotherapy

Clinical implications of pharmacogenomics for tardive dyskinesia

A unique mouse model for succinic semialdehyde dehydrogenase deficiency with implications for gamma hydroxybutyrate intoxication

Interethnic variability of ERCC2 polymorphisms

Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism

Association between methylenetetrahydrofolate reductase polymorphisms and the relapse of acute lymphoblastic leukemia: a meta-analysis

SHOW MORE ARTICLES

Multi-locus interactions predict risk for post-PTCA restenosis: an approach to the genetic analysis of common complex disease

Representational oligonucleotide microarray analysis (ROMA) in pharmacogenomics

Human sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies

Association between a G-protein beta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders

The ADAMs: a new therapeutic avenue?

Feeling below PAR: proteinase-activated receptors and the perception of neuroinflammatory pain

Will pharmacogenomics guide clinical practice?

Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response

CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians

Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content

Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity

Differential regulation of synaptic vesicle proteins by antidepressant drugs